Outpatient Treatment of Low-risk Pulmonary Embolism (Low Risk PE)
![]() |
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. |
ClinicalTrials.gov Identifier: NCT02355548 |
Recruitment Status :
Completed
First Posted : February 4, 2015
Last Update Posted : November 29, 2018
|
- Study Details
- Tabular View
- No Results Posted
- Disclaimer
- How to Read a Study Record
Condition or disease | Intervention/treatment |
---|---|
Pulmonary Embolism | Other: Outpatient Treatment of Pulmonary Embolism |
Study Type : | Observational |
Estimated Enrollment : | 200 participants |
Observational Model: | Cohort |
Time Perspective: | Prospective |
Official Title: | Rapid Risk Stratification for Outpatient Treatment of Low-risk Pulmonary Embolism |
Study Start Date : | December 2012 |
Actual Primary Completion Date : | December 2017 |
Actual Study Completion Date : | December 2017 |

Group/Cohort | Intervention/treatment |
---|---|
Outpatient Treatment
All patients eligible for the study will have their PE treated in the outpatient setting.
|
Other: Outpatient Treatment of Pulmonary Embolism
Patients who participate in the study will be treated for their pulmonary embolism in an outpatient setting instead of being hospitalized. |
- 90-day all-cause mortality, recurrent VTE, and Major Bleeding during outpatient treatment of Low-risk PE [ Time Frame: 90 Days ]This is a composite outcome of the above.
- Reduction of medical costs due to outpatient treatment. [ Time Frame: 90 Days ]
- Level of patient satisfaction as measured by survey. [ Time Frame: 90 Days Post study enrollment ]

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
Ages Eligible for Study: | 18 Years and older (Adult, Older Adult) |
Sexes Eligible for Study: | All |
Accepts Healthy Volunteers: | No |
Sampling Method: | Non-Probability Sample |
Inclusion Criteria:
- Pulmonary Embolism, diagnosed by CTA or high probability VQ Scan
- Total Pulmonary Embolism Severity Index (PESI) score <86
Exclusion Criteria:
- Massive Pulmonary Embolism: Hypotension with signs of right heart strain on CTA or Echocardiogram
- Sustained Systolic Blood Pressure (SBP) <95 mmHg during Emergency Department or observation stay.
- Age <18
- Pregnant
- Renal insufficiency (Creatinine Clearance <30)
- Hepatic Dysfunction (AST/ALT/ALP > 3 times upper limit of normal)
- Unreliable social situation or inability to follow up
- Contraindication to enoxaparin, warfarin and rivaroxaban
- Atrial or ventricular dysrhythmia(s)

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT02355548
United States, Utah | |
Intermountain Medical Center | |
Murray, Utah, United States, 84157 |
Principal Investigator: | Joseph Bledsoe, MD | Intermountain Health Care, Inc. |
Publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):
Responsible Party: | Intermountain Health Care, Inc. |
ClinicalTrials.gov Identifier: | NCT02355548 |
Other Study ID Numbers: |
1018558 |
First Posted: | February 4, 2015 Key Record Dates |
Last Update Posted: | November 29, 2018 |
Last Verified: | November 2018 |
Pulmonary Embolism Embolism Embolism and Thrombosis Vascular Diseases |
Cardiovascular Diseases Lung Diseases Respiratory Tract Diseases |